head and neck – Head and Neck Network https://headandnecknetwork.com Mon, 27 Apr 2026 15:27:51 +0000 it-IT hourly 1 https://wordpress.org/?v=7.0.2 https://headandnecknetwork.com/wp-content/uploads/2025/01/cropped-favicon-32x32.jpg head and neck – Head and Neck Network https://headandnecknetwork.com 32 32 CHEWING GUM REDUCES HPV AND ORAL CANCER-ASSOCIATED BACTERIA IN HEAD AND NECK SQUAMOUS CELL CARCINOMA https://headandnecknetwork.com/chewing-gum-reduces-hpv-and-oral-cancer-associated-bacteria-in-head-and-neck-squamous-cell-carcinoma/ https://headandnecknetwork.com/chewing-gum-reduces-hpv-and-oral-cancer-associated-bacteria-in-head-and-neck-squamous-cell-carcinoma/#respond Mon, 27 Apr 2026 15:27:51 +0000 https://headandnecknetwork.com/?p=2099 Emerging data published in Scientific Reports, demonstrates extracts from a bioengineered chewing gum to significantly reduce the levels of 3 microbes associated with head and neck squamous cell carcinoma (HNSCC).

The medicated chewing gum displayed substantial reductions in oral human papillomavirus (HPV), Porphyromonas gingivalis (P gingivalis), and Fusobacterium nucleatum (Fnucleatum).

The research evaluated a lablab bean–derived chewing gum containing the antiviral lectin (FRIL), for microbial loads in oral samples from patients with HNSCC. The goal was to asses HPV, Porphyromonas gingivalis and Fusobacterium nucleatum, which have been implicated in tumor progression.

The data analyzed saliva and oral rinse samples from patients with HNSCC and compared microbial levels following exposure to the investigational chewing gum extract.

Following treatment with the bean-derived lectin formulation, HPV levels were reduced by approximately 93% and 80% in saliva and oral rinse samples, respectively. The effect is attributed to FRIL-mediated binding of viral glycoproteins, which promotes aggregation and reduces viral availability for host cell entry.

Full article: https://www.pharmacytimes.com/view/emerging-data-shows-chewing-gum-reduces-hpv-and-oral-cancer-associated-bacteria-in-hnscc

]]> https://headandnecknetwork.com/chewing-gum-reduces-hpv-and-oral-cancer-associated-bacteria-in-head-and-neck-squamous-cell-carcinoma/feed/ 0 HEAD AN NECK SQUAMOUS CELL CANCERS – EMERGING TARGETED THERAPIES https://headandnecknetwork.com/head-an-neck-squamous-cell-cancers-emerging-targeted-therapies/ https://headandnecknetwork.com/head-an-neck-squamous-cell-cancers-emerging-targeted-therapies/#respond Fri, 12 Dec 2025 15:41:58 +0000 https://headandnecknetwork.com/?p=1857 HEAD AN NECK SQUAMOUS CELL CANCERS – EMERGING TARGETED THERAPIES

Systemic therapy remains the cornerstone of treatment for recurrent and metastatic (R/M) head and neck squamous cell cancers (HNSCC). However, there is a dearth of effective treatments beyond platinum combinations, anti-programmed death-1 (PD-1) agents and the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab. Recent years have seen several exciting new agents being tested in clinical trials. These are designed to target alternate oncogenic signaling pathways and have novel mechanistic compositions, including bi-specific antibodies and antibody-drug conjugates. 

A new study published in Frontiers delves into the clinical limitations of currently approved systemic therapies, explores novel agents in development, and highlights ongoing clinical trials using targeted therapies for this disease.

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1640960/full

]]> https://headandnecknetwork.com/head-an-neck-squamous-cell-cancers-emerging-targeted-therapies/feed/ 0 THERE IS A SPECIFIC DRUG FOR A GLIOBLASTOMA PATIENT: THE SUPPORT OF A CAREGIVER https://headandnecknetwork.com/there-is-a-specific-drug-for-a-glioblastoma-patient-the-support-of-a-caregiver/ https://headandnecknetwork.com/there-is-a-specific-drug-for-a-glioblastoma-patient-the-support-of-a-caregiver/#respond Fri, 13 Jun 2025 09:29:34 +0000 https://headandnecknetwork.com/?p=1342 THERE IS A SPECIFIC DRUG FOR A GLIOBLASTOMA PATIENT: THE SUPPORT OF A CAREGIVER


There is a specific DRUG for the glioblastoma patient that was developed at the lab and when this patient received the treatment, the tumor significantly regressed. It’s mostly the family and the support, the belief that the people have, that is going to be cured. The support of a caregiver is essential.

Video source: Dr. Javad Nazarian and @glioblastomaresearch

]]> https://headandnecknetwork.com/there-is-a-specific-drug-for-a-glioblastoma-patient-the-support-of-a-caregiver/feed/ 0 ROUND TABLE AND BOARD – Novelties and new avenues in the treatment of rare tumours https://headandnecknetwork.com/round-table-and-board-novelties-and-new-avenues-in-the-treatment-of-rare-tumours/ https://headandnecknetwork.com/round-table-and-board-novelties-and-new-avenues-in-the-treatment-of-rare-tumours/#respond Mon, 14 Apr 2025 11:03:16 +0000 https://headandnecknetwork.com/?p=1149 ROUND TABLE AND BOARD –
Novelties and new avenues in the treatment of rare tumours

12 Aprile 2025 – Hotel Majestic, Sant’Agnello – SORRENTO, Italy

The Round Table was attended by various experts from all over Italy to discuss the news in translational research applied to therapy in some oncological pathologies.
The focus board was aimed at implementing collaboration and the scientific network against cancer.

Dr. Raffaele Addeo and Prof. Michele Caraglia took part in the round table as moderators.
Topics covered:
* New advancements on the treatment of soft tissue sarcomas – Bruno Vincenzi (Responsabile UOS DH Oncologico, Fondazione Policlinico Universitario Campus Bio-Medico e Professore Ordinario in Oncologia presso l’Università Campus Bio-Medico di Roma)
* New protocols for the treatment of soft tissue leiomyosarcoma – Fernanda Picozzi (Dirigente Medico – U.O. Sarcomi e Tumori rari – Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”)
* Epigenetic modulation and Immunotherapy in cancer – Michele Maio (Ordinario di Oncologia dell’Università di Siena, direttore del Dipartimento Oncologico e del Centro di Immuno-Oncologia dell’Azienda ospedaliero-universitaria senese – Siena) e Annamaria Di Giacomo, (Professore associato di Oncologia Medica presso l’Università di Siena)
* New challenges in the treatment of melanoma – Teresa Troiani (Dipartimento di Medicina di Precisione Università degli studi della Campania “Luigi Vanvitelli” – Napoli)
* Liquid biopsy in melanoma management – Marco Tucci (Professore Associato Oncologia Medica, Università degli Studi di Bari “Aldo Moro”)
* New teachings coming from ADC in breast cancer – Michelino De Laurentiis (Direttore Oncologia Medica Senologica Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”)

* New challenges in the treatment of glioblastoma – Raffaele Addeo (Direttore UOC di Oncologia P.O. “San Giovanni di Dio” di Frattamaggiore (Na)
* Immunological check point inhibitors in the treatment of head and neck cancers: opportunities and concerns – Francesco Perri (Direttore ad interim UOC Oncologia Testa Collo Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”)
* NTRK fusion as a new target in oncology – Michele Caraglia (Professore Ordinario Dipartimento di Medicina di Precisione Università degli studi della Campania “Luigi Vanvitelli” – Napoli)
* Searching for rare mutations: the point of view of the Pathologists – Andrea Ronchi (Università degli studi della Campania “Luigi Vanvitelli” – Napoli)
Round Table organized by MACAON scarl in collaboration with Imr Consulting.

]]> https://headandnecknetwork.com/round-table-and-board-novelties-and-new-avenues-in-the-treatment-of-rare-tumours/feed/ 0